The Hetero Ring Is Five-membered Patents (Class 514/461)
  • Patent number: 10709749
    Abstract: The present invention relates to a composition for preventing and treating cancer-related fatigue, characterized by containing a new processed ginseng powder or a new processed ginseng extract having an increased amount of a ginsenoside constituent, which was previously minute, by preparing a saponin-decomposing enzyme and subsequently using hydrolysis by the prepared saponin-decomposing enzyme and an organic acid. The composition according to the present invention can be very effectively used for preventing and treating cancer-related fatigue, the most destructive and universal side effect, which is caused by cancer itself or occurs in association with the treatment of cancer.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: July 14, 2020
    Assignee: GREEN CROSS WELLBEING CORPORATION
    Inventors: Young Hyo Yoo, Jeom Yong Kim, Joo Young Kim, Sun Kyu Park
  • Patent number: 10647655
    Abstract: An improved method for the synthesis of substantially pure Permethrin having purity greater than 99.5% by Gas Chromatography provided. The embodiments also relates to a purification process of Permethrin by recrystallization from methanol-water mixture.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: May 12, 2020
    Assignee: BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.
    Inventors: Manik Reddy Pullagurla, Mecheril Valsan Nanda Kumar, Madhusudhana Rao Veligetla, Jagadeesh Babu Rangisetty
  • Patent number: 10525031
    Abstract: Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 7, 2020
    Assignee: Avoscience, LLC
    Inventor: Richard Huber
  • Patent number: 10512628
    Abstract: There is provided in accordance with an embodiment of the disclosure a spray-on composition for the treatment and prevention of insect or arachnid infestation on a mammal comprising between 0.1% and 1.0% by weight dinotefuran. There is also provided in accordance with an embodiment of the disclosure a method for treatment of an animal at risk of insect or arachnid infestation comprising topically administering to the coat of the animal a composition comprising between 1 and 50 mg dinotefuran per kilogram of animal weight. Optionally, topically administering includes spraying on a majority of the area of the coat of the animal.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: December 24, 2019
    Assignee: SOLANO S.P. LTD.
    Inventors: Amnon Vardi, Amir Kafri, Nimrod Vardi
  • Patent number: 10494356
    Abstract: The present disclosure relates to a compound having the activity of promoting osteoblast differentiation and inhibiting adipocyte differentiation and a preparation method thereof. The novel compound of the present disclosure increases the expression of the gene ALP involved in the differentiation of osteoblasts, regulates expression of the genes PPAR?, aP2 and CD36 involved in the differentiation of adipocytes, increases bone mineral density (BMD) in an ovariectomized osteoporosis animal model and decreases adipocytes in the bone marrow. Therefore, it can be used as an active ingredient of a medication or a health functional food useful for metabolic bone disease or obesity.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: December 3, 2019
    Assignee: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Hyun Suk Kim, Kimoon Park, Min-hyuk Bang, Hee-Jin Yang, Yun Mi Lee, Ki Hyun Kim
  • Patent number: 10144736
    Abstract: The invention provides 4,6-di- and 2,4,6-tri-substituted pteridine derivatives with a specific substitution pattern which exhibit a significant and selective activity against certain types of viral infections, in particular selectively inhibit replication of Flaviridae such as the hepatitis C virus, and are useful for the prevention and treatment of such viral infections.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: December 4, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Piet AndréMaurits Maria Herdewijn, Steven Cesar Alfons De Jonghe, William John Watkins, Lee Shun Chong
  • Patent number: 10085967
    Abstract: The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: October 2, 2018
    Assignee: King Abdullah University of Science and Technology
    Inventors: Megbubah Essack, Vladimir Bajic, Aleksandar Radovanovic
  • Patent number: 10016385
    Abstract: A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: July 10, 2018
    Inventor: Alan B. Cash
  • Patent number: 9968585
    Abstract: Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: May 15, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventor: Hiroji Yanamoto
  • Patent number: 9808473
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is halo; —CN; alkyl; cycloalkyl; alkoxy; phenyl, which is optionally substituted one or twice independently by alkyl, halo, or —CN; or a thiophene ring, which is optionally substituted once or twice independently by alkyl. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: November 7, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James Francis Dropinski, Milana Maletic, Jae-Hun Kim, Deyou Sha
  • Patent number: 9732363
    Abstract: The present invention provides a growth method for a microbe which can enhance the growth of the microbe without removing growth inhibitors from a saccharified solution. The growth method for a microbe comprises the steps of: obtaining a mixed saccharified solution by diluting the saccharified solution containing a growth inhibitor which inhibits the growth of the microbe with a sugar solution having a smaller growth inhibitor concentration than that of the saccharified solution such that the growth inhibitor concentration is decreased; and allowing the microbe to grow by adding the microbe to the mixed saccharified solution.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 15, 2017
    Assignee: HONDA MOTOR CO., LTD.
    Inventors: Yoshiki Tsuchida, Norihiko Tsukagoshi, Masaki Ueyama
  • Patent number: 9687503
    Abstract: The present invention comprises methods and compositions for delivery devices More particularly, the present invention comprises methods and compositions for devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having oxygen and optionally active agents incorporated therein. The matrix may be formed into any desired shape for treatment of compromised tissue or for delivery of oxygen to a localized environment.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: June 27, 2017
    Assignee: Avent, Inc.
    Inventors: Bruce L. Gibbins, Lance D. Hopman
  • Patent number: 9676675
    Abstract: The present disclosure relates to multi-effect tree dripping liquid and usage thereof. The dripping liquid includes coconut, astragalus and ephedra root extract, glucose, coenzyme A, adenosine triphosphate, vitamin B1, vitamin C, dexamethasone sodium phosphate, seaweed essence, brassinolide, boric acid, manganese sulfate, zinc sulfate, a plant growth hormone, their volume percentages are 20% to 30% of coconut fumet, 5% to 13% of coconut meat extract, 28% to 38% of astragalus and ephedra root extract, 10% to 15% of 50% glucose injection, 2% to 7% of 99.8% seaweed essence, 5% to 11% of 0.0016% brassinolide, 2% to 7% of potassium sorbate, boric acid, manganese sulfate, zinc sulfate, plant growth hormone, a trace amount of preservative, distilled water. The multi-effect tree dripping liquid can achieve the purposes of supplying nutrients, balancing the water content inside the bodies of seedlings, preventing water transpiration, fast healing trauma root wounds, promoting early rooting, and preventing infection.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: June 13, 2017
    Assignee: Lingnan Landscape Co., Ltd.
    Inventor: Mian Liu
  • Patent number: 9606109
    Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 28, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Rakesh Sindhi
  • Patent number: 9591852
    Abstract: In certain embodiments, the present invention relates to compounds, compositions, and methods for disrupting biofilms. In some embodiments, the compounds and compositions comprise unsaturated long chain alcohols and/or aldehydes, or combinations of such compounds. In further embodiments, the present invention contains therapeutic actives to help reduce and/or eradicate the bacteria in the biofilm once the film is disrupted.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: March 14, 2017
    Assignee: McNeil-PPC, Inc.
    Inventors: Carolyn J. Mordas, Robert J. Gambogi
  • Patent number: 9289415
    Abstract: This disclosure provides agents, compositions and methods of treating cancer by inhibiting histone lysine specific demethylase 1 (LSD1) and/or and a histone lysine specific demethylase 2 (LSD2). Agents and compositions comprise statins and/or inhibitors of LSD1/2.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: March 22, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Yujiang Geno Shi, Christine Guo Lian
  • Patent number: 9290427
    Abstract: The present invention relates to the field of anti-invasive compounds and methods for predicting the anti-invasive activity of said compounds, as well as their use in the prevention and/or treatment of diseases associated with undesired cell invasion; in particular, this invention relates to the field of anti-invasive chalcone-like compounds.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: March 22, 2016
    Assignee: Universiteit Gent
    Inventors: Marc Bracke, Christian Stevens, Tine De Ryck, Bart Roman, Barbara Vanhoecke
  • Patent number: 9089576
    Abstract: The invention relates to a medicament which comprises a peptide extract of avocado and which can also comprise a composition containing D-mannoheptulose an/or perseitol, such as a water-soluble extract of avocado sugars, and/or a peptide extract of lupine. The inventive medicament is intended for the treatment and/or prevention of illnesses that are linked to an alteration in innate and/or acquired immunity, through an increase in the production of anti-microbial peptides, preferably hBD-2, without inducing inflammatory reactions, irritations or intolerances.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: July 28, 2015
    Assignee: LABORATOIRES EXPANSCIENCE
    Inventors: Antoine Piccirilli, Nathalie Piccardi, Philippe Msika, François Paul, Stéphanie Bredif
  • Publication number: 20150140076
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Patent number: 9034916
    Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: May 19, 2015
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Won Gon Kim, Baek Soo Han, Kyoung Shim Kim, Kwang Soo Kim, Young Mi Kang, Yu Jin Kim, Chun Hyung Kim, Mi Jin Sohn, Hoe Yune Jung
  • Publication number: 20150133540
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventor: Robert H. Bedoukian
  • Publication number: 20150133442
    Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Inventors: Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
  • Patent number: 9023874
    Abstract: The invention relates to alkylsulfide derivatives compounds of formula I as hereunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to methods for controlling invertebrate pests by using these compounds and to plant propagation material and to agricultural and veterinary compositions comprising said compounds. wherein U, R1, R2, R3U, X, n and p are defined as in the description.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: May 5, 2015
    Assignee: Merial, Inc.
    Inventors: Sebastian Soergel, Ralph Paulini, Steffen Gross, Carsten Beyer, Matthias Pohlman, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Douglas D. Anspaugh, Sarah Thompson, Vincent Salgado
  • Publication number: 20150111943
    Abstract: The hydroxymethylfurfural derivative is represented by the general formula (A) (wherein, R is selected from the group consisting of the following formula (I), (II) HOOCCH2COCO—, (III) HOOCCH2CH2COCO—, and (IV) a hydrogen atom).
    Type: Application
    Filed: December 20, 2012
    Publication date: April 23, 2015
    Inventors: Hiroshi Nishioka, Tomohiro Ito, Takahiro Maeda
  • Publication number: 20150105460
    Abstract: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: April 16, 2015
    Inventors: Weiwei Su, Yonggang Wang, Fengyin Liang, Ning Wang, Zhong Pei, Haibin Liu
  • Patent number: 9000034
    Abstract: An antibiotic composition including erythorbyl laurate as an active ingredient and a use thereof are disclosed. Erythorbyl laurate is confirmed to have antibiotic effects on Gram-positive bacteria and thus is used as an antibiotic agent in foods, cosmetics, feeds, and the like and utilized in the form of a hand cleaner and other medicines for external application.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: April 7, 2015
    Assignee: SNU R&DB Foundation
    Inventors: Pahn Shick Chang, Kyung Min Park, Da Eun Lee, Dong Hyun Kang
  • Publication number: 20150087677
    Abstract: The present invention relates to a method for treating platinum drugs induced vestibulotoxicity, comprising administering a compound that impairs or prevents accumulation of platinum drugs within vestibular hair cells and/or vestibular primary neurons.
    Type: Application
    Filed: November 28, 2014
    Publication date: March 26, 2015
    Inventor: Sophie Gaboyard-Niay
  • Publication number: 20150072969
    Abstract: The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40 comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).
    Type: Application
    Filed: February 27, 2013
    Publication date: March 12, 2015
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: Sanjay Kumar, Rajiv Sharma, Vishal Ashok Mahajan, Sangameshwar Prabhakar Sawargave
  • Patent number: 8969410
    Abstract: A pharmaceutical composition for alleviating or treating gout and the applications thereof are provided. The pharmaceutical composition includes p-coumaryl diacetate as an active ingredient.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 3, 2015
    Assignee: Industrial Technology Research Institute
    Inventors: Ying-Chu Shih, Jenn-Line Sheu, Cheng-Yu Lee, Jir-Mehng Lo, Yi-Ching Lee, Ying-Fei Tsai, Yi-Cheng Cheng
  • Patent number: 8969390
    Abstract: The invention relates to liquid compositions which contain a) from 40 to 99.9% by weight of sorbitan monocaprylate and b) from 0.1 to 60% by weight of one or more antimicrobial substances selected from the group consisting of the components b1) to b5): b1) specific organic acids and the salts thereof, b2) specific formaldehyde donors, b3) specific isothiazolinones, b4) specific paraben esters and the salts thereof, and b5) specific pyridones and the salts thereof. The liquid compositions are suitable for the production of cosmetic, dermatological or pharmaceutical products.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: March 3, 2015
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Peter Klug, Sonja Gehm, Guiseppina Kluth, Franz-Xaver Scherl, Maurice Frederic Pilz
  • Patent number: 8957111
    Abstract: A compound of formula (ascorbate)2Sr:(M+a)x(ascorbate)y, or ascorbate)2Sr:Ca(ascorbate)2, a composition containing the same, a method of making the same and a method of administering the same as a supplement.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: February 17, 2015
    Assignee: Nutraceutical Corporation
    Inventors: Shayne Morris, Richard Bush
  • Publication number: 20150044293
    Abstract: Radioprotector compounds including 3,3?-diindolylmethane (DIM) analogs, are provided. Further provided are methods for their use in reducing or preventing radiation damage, killing a tumor cell and protecting a non-tumor cell, and treating cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Applicant: Georgetown University
    Inventors: Eliot M. Rosen, Milton Brown, Saijun Fan, Thomas Walls, Kathryn E. Ditmer
  • Patent number: 8952192
    Abstract: Provided are compositions and methods for modulating quorum sensing in microbes. The compounds are AI-2 analogs and as such have structures similar to 4,5-dihydroxy-2,3-pentanedione that can act as agonists/antagonists of quorum sensing. The compounds are useful for modulating quorum sensing in bacteria and can be used in methods for prophylaxis or therapy of bacterial infections and for reduction of biofilms.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: February 10, 2015
    Assignee: University of Maryland, College Park
    Inventors: Herman O. Sintim, William E. Bentley, Varnika Roy, Jacqueline Smith, Reza Ghodssi, Mariana Tsacoumis Meyer
  • Patent number: 8952056
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: February 10, 2015
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Sergi Gulnik, John W. Erickson
  • Patent number: 8946280
    Abstract: The present invention relates to novel strigolactam derivatives of formula (I) to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controlling the growth of plants and/or promoting the germination of seeds.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: February 3, 2015
    Assignee: Syngenta Participations AG
    Inventors: Mathilde Denise Lachia, Alain De Mesmaeker, Hanno Christian Wolf, Pierre Joseph Marcel Jung
  • Patent number: 8946289
    Abstract: Provided are manassantin compounds and methods of using the compounds. Provided are methods of treating a disease, the method comprising administering a compound according to Formula I. Further provided are pharmaceutical compositions comprising compounds according to Formula I. Also provided are methods of inhibiting HIF-1 in a cell, the methods comprising administering to the cell a compound according to Formula I.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: February 3, 2015
    Assignee: Duke University
    Inventors: Jiyong Hong, Mark Dewhirst, Hyoungsu Kim, Amanda C. Kasper, Eui Jung Moon, Yongho Park, Ceshea M. Wooten
  • Publication number: 20150011620
    Abstract: The present invention relates to the field of anti-invasive compounds and methods for predicting the anti-invasive activity of said compounds, as well as their use in the prevention and/or treatment of diseases associated with undesired cell invasion; in particular, this invention relates to the field of anti-invasive chalcone-like compounds.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 8, 2015
    Inventors: Marc Bracke, Christian Stevens, Tine De Ryck, Bart Roman, Barbara Vanhoecke
  • Patent number: 8927593
    Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: January 6, 2015
    Assignee: Glaxo Group Limited
    Inventors: Pek Yoke Chong, John Brad Shotwell
  • Patent number: 8921365
    Abstract: The invention relates to the use of a pharmaceutical composition for the local treatment or prevention of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises primarily intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises primarily extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilization or rupture of the bacterial cell wall.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: December 30, 2014
    Assignee: Biomet Deutschland GmbH
    Inventor: Nicole Duewelhenke
  • Publication number: 20140371306
    Abstract: The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.
    Type: Application
    Filed: May 20, 2014
    Publication date: December 18, 2014
    Applicant: UNIVERSITÄT INNSBRUCK
    Inventors: Hermann STUPPNER, Stefan SCHWAIGER, David BERNHARD, Günther LAUFER
  • Publication number: 20140363388
    Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.
    Type: Application
    Filed: January 13, 2014
    Publication date: December 11, 2014
    Applicant: UNIGEN, INC.
    Inventors: Sandip K. Nandy, Jiyun Liu, Alexandre Mikhailovitch Nesterov, Carmen Hertel, Abeysinghe A. Padmapriya
  • Patent number: 8889734
    Abstract: The subject of the present invention is a novel process for the preparation of N-[2-n-butyl-3-{4-[(3-dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide of formula I: and the new intermediates of the preparation process.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: November 18, 2014
    Assignee: SANOFI
    Inventors: Antal Friesz, Zsolt Dombrady, Mariann Csatarine Nagy
  • Publication number: 20140336185
    Abstract: Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP (1-42), PTH (1-34), Glucagon (1-29), GLP-2 (1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.
    Type: Application
    Filed: May 31, 2012
    Publication date: November 13, 2014
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Thomas Fowler, Andrew Novak, Premji Meghani, Enugurthi Brahmachary, Adam Richard Yeager
  • Patent number: 8877754
    Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 4, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerald Juergen Roth, Martin Fleck, Heike Neubauer, Bernd Nosse
  • Patent number: 8877710
    Abstract: The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: November 4, 2014
    Assignee: Righospitalet
    Inventors: Par Johansson, Sisse Rye Ostrowski
  • Publication number: 20140323510
    Abstract: Disclosed herein is a compound of the formula Therapeutic methods, compositions, and medicaments, related thereto are also disclosed.
    Type: Application
    Filed: May 8, 2014
    Publication date: October 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Yariv Donde, Jeremiah H. Nguyen
  • Publication number: 20140323562
    Abstract: The present application provides compound of Formula X wherein A is an optionally substituted aliphatic or an optionally substituted aryl, and B is a moiety that stabilizes the partial positive charge at the carbon adjacent the divalent sulfur. The compound of Formula X is useful as a reversible antioxidant in a variety of applications. Also provided are methods of synthesizing the compound of Formula X.
    Type: Application
    Filed: November 23, 2012
    Publication date: October 30, 2014
    Inventors: Philip Jessop, Paul David Thornton, Shannon Marie Decker, Derek Pratt, Feng Zheng, Donna Lynn Leger
  • Patent number: 8871679
    Abstract: Fungicidal mixtures, comprising as active components 1) at least one 1-methylpyrazol-4-ylcarboxanilide of the formula I where R1?C1-C4-alkyl or C1-C4-haloalkyl, R2=hydrogen or halogen, X=hydrogen or halogen, Q=direct bond, a cyclopropylene or an anellated bicyclo[2.2.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: October 28, 2014
    Assignee: BASF SE
    Inventors: Markus Gewehr, Ulf Groeger, Egon Haden, Michael Vonend
  • Patent number: 8871802
    Abstract: The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: October 28, 2014
    Assignee: Zhoushan HaiZhongZhou Xinsheng Pharmaceuticals Co., Ltd.
    Inventors: Zhiwei Jiang, Aijin Wang, Xian Li, Qingrong Li, Hongwei Hu, Jiali Xu, Yuesong Hu, Yan Ye
  • Patent number: RE45324
    Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: January 6, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Brian Austad, Charles E. Chase, Francis G. Fang